Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Entecavir Is 1st-Choice Drug for Chronic Hepatitis B: Dr Kumada
April 2, 2007
- Korosho Orders Chugai to Issue "Dear-Doctor Letter" on Tamiflu
April 2, 2007
- NEW PRODUCTS
April 2, 2007
- Relenza in Short Supply
April 2, 2007
- Eli Lilly to Enhance Presence in GP Market: Mr Crenshaw
April 2, 2007
- Council to Propose Strategies to Enhance Global Competitiveness
April 2, 2007
- Eisai Embarks on Antibody Pharmaceuticals Business by Acquiring Morphotek
April 2, 2007
- Korosho Proposes 7 Measures to Promote Innovation
March 26, 2007
- Japan-China Medical Cooperation Initiatives to Symbolize Fraternity: Mr Niwa
March 26, 2007
- R&D NEWS IN BRIEF
March 26, 2007
- FPMAJ to Propose NHI Pricing System Reform Plan in August
March 26, 2007
- Results of J-LIT Subanalysis Published: Banyu
March 26, 2007
- Required Nos. of Japanese Subjects Are Not Exorbitant: Mr Mori from PMDA
March 26, 2007
- Philips Simplicity Event in Hong Kong Highlights Philips' "Sense and Simplicity" in Healthcare
March 26, 2007
- REGULATORY NEWS IN BRIEF
March 26, 2007
- Takeda Acquires Paradigm of the UK
March 26, 2007
- Operating Profit Rate for 28 FJPWA-Affiliated OTC Drug Wholesalers Up 0.41 Points
March 26, 2007
- Nippon Chemiphar to Enter Chinese Market, Expand Generic Business
March 26, 2007
- Spread of Use of Steroids Reduces Asthma Deaths: GSK Seminar
March 26, 2007
- SymBio Licenses AB-1001 from Abeille
March 26, 2007
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…